Markets
Insmed Stock Soars 17%, Adding $3.6 Billion, As It Lifts Sales Forecasts For Its Two Drugs
Insmed raised the low end of 2026 sales forecasts for Brinsupri and Arikayce, and third-quarter revenue rose 268.4% from a year earlier.
Insmed (INSM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Insmed raised the low end of 2026 sales forecasts for Brinsupri and Arikayce, and third-quarter revenue rose 268.4% from a year earlier.
Earnings
Brinsupri sales rose 29% from the second quarter, and the net loss narrowed to $100.3 million from $370.0 million a year earlier.
SEC Filings
The drugmaker cites tight European healthcare funding and shifting US policy, and flags a pending $35.0 million AstraZeneca milestone.
SEC Filings
Each new independent director gets restricted stock units with a grant-date fair value of about $585,000, plus a committee seat, an 8-K shows.
Earnings
The biotech reaffirmed 2026 revenue guidance for BRINSUPRI and ARIKAYCE and has started a search for her successor.